Eupraxia Pharmaceuticals Inc (EPRX) - Total Liabilities

Latest as of September 2025: CA$5.43 Million CAD ≈ $3.93 Million USD

Based on the latest financial reports, Eupraxia Pharmaceuticals Inc (EPRX) has total liabilities worth CA$5.43 Million CAD (≈ $3.93 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EPRX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Eupraxia Pharmaceuticals Inc - Total Liabilities Trend (2017–2024)

This chart illustrates how Eupraxia Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Eupraxia Pharmaceuticals Inc total assets.

Eupraxia Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Eupraxia Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Community Health Systems Inc NYSE:CYH	USA	$13.34 Billion
Studio Dragon Corporation KQ:253450	Korea	₩234.22 Billion
Shenzhen Glory Medical Co Ltd SHE:002551	China	CN¥631.49 Million
Chongqing Sansheng Building Materials Co Ltd SHE:002742	China	CN¥895.14 Million
Kolte - Patil Developers Limited NSE:KOLTEPATIL	India	Rs-12.05 Billion
EQT Holdings Ltd AU:EQT	Australia	AU$207.09 Million
Beijing Bashi Media Co Ltd SHG:600386	China	CN¥2.08 Billion
Jiangsu Lidao New Material Co Ltd Class A SHG:603937	China	CN¥1.02 Billion

Liability Composition Analysis (2017–2024)

This chart breaks down Eupraxia Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Eupraxia Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	23.98	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.04	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.04	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Eupraxia Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Eupraxia Pharmaceuticals Inc (2017–2024)

The table below shows the annual total liabilities of Eupraxia Pharmaceuticals Inc from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	CA$4.46 Million ≈ $3.23 Million	-82.53%
2023-12-31	CA$25.55 Million ≈ $18.48 Million	+76.03%
2022-12-31	CA$14.51 Million ≈ $10.50 Million	+24.36%
2021-12-31	CA$11.67 Million ≈ $8.44 Million	-49.52%
2020-12-31	CA$23.12 Million ≈ $16.72 Million	+7.94%
2019-12-31	CA$21.42 Million ≈ $15.49 Million	+49.30%
2018-12-31	CA$14.34 Million ≈ $10.38 Million	+1849.47%
2017-12-31	CA$735.82K ≈ $532.28K	--

About Eupraxia Pharmaceuticals Inc

TO:EPRX Canada Biotechnology

Market Cap

$414.38 Million

CA$572.83 Million CAD

Market Cap Rank

#13345 Global

#394 in Canada

Share Price

CA$11.31

Change (1 day)

-1.65%

52-Week Range

CA$7.50 - CA$12.50

All Time High

CA$12.50